Actelion to Present at the 12th Annual BIO CEO & Investor Conference

(Thomson Reuters ONE) - Actelion Pharmaceuticals Ltd / Actelion to Present at the 12th Annual BIO CEO & Investor Conference processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ALLSCHWIL/BASEL, SWITZERLAND - 05 February 2010- Actelion Ltd (SIX: ATLN)announced today that Roland Haefeli, Vice Pesident, Investor Relations & PublicAffairs and member of the Actelion executive committee, will present at theupcoming BIO CEO & Investor Conference on Monday, February 8, 2010 at 9:30 a.m.Eastern time / 3:30 p.m. local time at the Waldorf Astoria Hotel in New YorkCity.To access the live and subsequently archived webcast of the presentation, visit"Events" in the Investor Relations section of Actelion's Web siteathttp://www.actelion.com , Investors section.  Anarchived replay will be available for 3 months beginning 24 hours after the livepresentation.###Actelion Ltd.Actelion Ltd is a biopharmaceutical company with its corporate headquarters inAllschwil/Basel, Switzerland.  Actelion's first drug Tracleer®, an orallyavailable dual endothelin receptor antagonist, has been approved as a therapyfor pulmonary arterial hypertension.  Actelion markets Tracleer® through its ownsubsidiaries in key markets worldwide, including the United States (based inSouth San Francisco), the European Union, Japan, Canada, Australia andSwitzerland. Actelion, founded in late 1997, is a leading player in innovativescience related to the endothelium - the single layer of cells separating everyblood vessel from the blood stream.  Actelion's over 2, 200 employees focus onthe discovery, development and marketing of innovative drugs for significantunmet medical needs.  Actelion shares are traded on the SIX Swiss Exchange(ticker symbol: ATLN).For further information please contact:Roland HaefeliVice President, Investor Relations & Public AffairsActelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil+41 61 565 62 62+1 646 737 49 72www.actelion.com <./www.actelion.com>[HUG#1381302] --- End of Message --- Actelion Pharmaceuticals LtdGewerbestrasse 16 Allschwil SwitzerlandWKN: 936767;ISIN: CH0010532478; Press Release PDF: http://hugin.info/131801/R/1381302/340593.pdf

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 05.02.2010 - 17:36 Uhr
Sprache: Deutsch
News-ID 12143
Anzahl Zeichen: 0

contact information:
Town:

Allschwil

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 151 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Actelion to Present at the 12th Annual BIO CEO & Investor Conference"
steht unter der journalistisch-redaktionellen Verantwortung von

Actelion Pharmaceuticals Ltd (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Zavesca® (miglustat) receives positive vote from the FDA's Endocrinologic ...

Actelion to Present at the 28th Annual J.P. Morgan Healthcare Conference ...

Actelion reports arbitration results between subsidiary CoTherix, Inc. and Asahi ...

Alle Meldungen von Actelion Pharmaceuticals Ltd